17,261 trials
Chronic HCV Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 100.0; 100.0; 83.3 percentage of participants
Opioid-Related Disorders
Primary: Subjective Opioid Withdrawal Scale Score (SOWS) — 16; 4; 24 units on a scale
Recurrent Prostate Cancer
Primary: Patients With PSA <4 ng/mL at the End of the Study — 17 participants
Mild Cognitive Impairment · Mild Alzheimer's Disease
Primary: Change From Baseline in Total Sleep Time (TST) After 4 Weeks of Treatment, Based on PSG Measurement. — 6.43; -12.53; -19.41; 14.48 Minutes
Breast Cancer
Primary: The Number of Participants With a Significant Increase in Perfusion Defects (PD) — 1; 2; 3; 5 participants — p=0.6
Hepatitis C Virus Infection
Primary: Change From Baseline in Magnetic Resonance Spectroscopy (MRS) Metabolic Ratio at 4 Weeks After Discontinuation of Therapy: NAA + NAAG — -0.03; -0.01; -0.03; -0.09 ratio…
Congenital Fibrinogen Deficiency · Afibrinogenemia
Primary: Ratio of Octafibrin/FIBRYGA® to Haemocomplettan® P/RiaSTAP(TM) for Fibrinogen Activity Normalized Area Under the Curve Unstandardized — 1.196 ratio
Dengue · Dengue Hemorrhagic Fever · Dengue Virus
Primary: Percentage of Participants With Antibody Titers of ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain Before and Following Each Injection With Sanofi Pasteur's…
Muscle Pain · Joint Pain
Primary: Change in Musculoskeletal Symptom Sub-scale on the Breast Cancer Prevention Trial Symptom Scale — -0.2; -0.5 units on a scale — p=0.38
Anxiety
Primary: Change in Anxiety as Measured by Visual Analog Scale — 3.4; 2.1; 1.6; 1.9 units on a scale — p=<0.001
Back Pain
Primary: Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity — 8.3; 8.1 units on a scale — p=0.7
NSCLC
Primary: Objective Response Rate (ORR) in Each Study Arm Based on Independent Central Radiology Review — 0; 0; 15; 6 participants — p=0.2895
Malignant Glioma
Primary: LBH589 Maximum Tolerated Dose (MTD) [Phase I] — 30 mg/day orally, 3x per wk, every other wk
Heart Failure
Primary: Arbitrary Accelerometry Units (AAU) (Phase I) — 9370; 9538 accelerometry units
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC) — 2.67; 0.83; -0.33; -0.17 units on…